论文部分内容阅读
目的:Meta分析食管癌放化疗后复发再程放疗与其他疗法疗效和不良反应。n 方法:通过计算机检索PubMed、Embase、Cochrane Library、CNKI、万方等数据库，搜集有关食管癌放化疗后复发再程放疗与其他治疗方法比较的临床对照研究。检索时间为建库至2020年4月。采用RevMan 5.1软件进行分析，组间差异采用n RR及95%n CI描述。n 结果:根据纳入排除标准最终纳入11篇文献，包括842例患者。n Meta分析结果显示再程放疗组与手术组相比总生存率略低(n RR＝0.40，95%n CI为0.27~0.61，n P<0.001)，与单纯化疗组相比则得到了提高(n RR＝2.91，95%n CI为1.43~5.95，n P＝0.003)。再程放疗组与手术组治疗相关死亡率相近(n RR＝0.53，95%n CI为0.14~1.98，n P＝0.350)，但手术组发生率较高(1.7%~11.4%∶1.9%~2.8%)。n 结论:再程放疗是放化疗后复发食管癌的有效治疗手段，可作为临床患者的选择方案。“,”Objective:To compare the efficacy and adverse events of salvage radiotherapy and other treatments for recurrent esophageal cancer after chemoradiotherapy in this Meta-analysis.Methods:Databases including PubMed, Embase, Cochrane Library, CNKI and Wanfang data were searched from the inception to April 2020 to collect the clinical trials which comparatively analyzed the efficacy and safety between radiotherapy and other treatments for recurrent esophageal cancer after chemoradiotherapy. Meta-analysis was performed using RevMan 5.1 software. RR and 95%n CI were used to describe the differences among different groups.n Results:According to the inclusion and exclusion criteria, a total of 11 clinical trials involving 842 patients were included. Meta-analysis showed that the overall survival in the salvage radiotherapy group was significantly lower than that in the salvage esophagectomy group (n RR=0.40, 95%n CI: 0.27-0.61, n P<0.001), whereas significantly higher than that in the chemotherapy group (n RR=2.91, 95%n CI: 1.43-5.95, n P=0.003). There was no significant difference in the treatment-related mortality between the salvage radiotherapy and salvage esophagectomy groups (n RR=0.53, 95%n CI: 0.14-1.98, n P=0.350), but the incidence was significantly higher in the salvage esophagectomy group (1.7%-11.4% n vs. 1.9%-2.8%).n Conclusion:Salvage radiotherapy is an effective treatment for recurrent esophageal cancer after chemoradiotherapy, which can be regarded as one choice for clinical patients.